Appendix Table C5b(1)-Update. Adherence outcomes for VAP which control for secular trend or confounding from the update search

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Study** | **Infection** | **Intervention** | **Pre-Intervention rate of adherence** | **Post-intervention rate of adherence** | **Post-intervention rate of adherence Statistical Analysis** | **Follow-up Months** |
| Barrera, Colombia – 2011 | CAUTI, CLABSI, VAP | hand hygiene promotion |   |   | ABHR use: increase 9.2% monthly, p<0.001 | 46 |
| Cheema, United States - 2011 | VAP | Phase 3: VAP bundle with flowsheet |   | Phase 2: 48-78% |   | 42 |
| Harris, United States - 2011 | CLABSI, VAP | hand hygiene, vap bundle, standardizing central line care |   |   |   | 13 |
| Lilly, United States – 2011 | CLABSI, VAP | tele-ICU, providing care from a remote location | VAP: 33% | VAP: 52% | OR: 2.20 (95% CI: 1.79 to 2.70), p<0.001 | 15 |
| Morris, Scotland – 2011 | VAP | VAP bundle - sedation holiday, elevated bed, oral care, with checklist and feedback |   | for 2 parts of bundle (head tilt & oral care): >95%; for all 3 components in bundle: 70% |   | 12 |
| Speroff, United States - 2011 | CLABSI, VAP | Virtual Collaborative Group |   | Virtual Collaborative: Clinical Tool Use: 61%; Data Tool Use: 56%; Prevention Strategy Use: 69%;Toolkit Group: Clinical Tool Use: 49%; Data Tool Use: 30%; Prevention Strategy Use: 54% | t-test: Clinical Tool Use: p=0.23; Data Tool Use: p=0.004; Prevention Strategy Use: p=0.017 | 18 |